NTI 1.28% 7.7¢ neurotech international limited

Ann: Trading Halt, page-8

  1. 1,415 Posts.
    lightbulb Created with Sketch. 565


    Primary outcome [1] - Change in Clinical Global Impression Scale -Improvement (CGI-I)This is a 7-point scale measuring symptom change from baseline

    Primary outcome 2 - Change in Vineland Adaptive Behaviour Scales, Third Edition (Vineland-3) Parent/Caregiver Form.Used to measure adaptive functioning across three core domains (Communication, Daily Living Skills, and Socialization), and two optional domains (Motor Skills and Maladaptive Behaviour); items are rated on a 3-point scale (0=never; 1=sometimes; 2=usually or often). The core domains sum to a total Adaptive Behaviour Composite.

    There are Many secondary outcomes / measures. Very comprehensive so gives (me) an understanding of why it takes so long to compile the results and understand drivers for any outliers. There will be a cornucopia of other data collected against the above measures for other trials to compare to. Also blood as youve mentioned, liver and renal tests for safety.

    All the detail here: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381885&isReview=true although updating the CTR site isnt one of NTI or Fenix's strong points.

    GLAH
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
7.7¢
Change
-0.001(1.28%)
Mkt cap ! $78.33M
Open High Low Value Volume
7.9¢ 8.1¢ 7.7¢ $54.26K 684.2K

Buyers (Bids)

No. Vol. Price($)
3 98220 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 21369 1
View Market Depth
Last trade - 15.59pm 22/07/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.